21 May 2013
Keywords: vical, inovio, start, cancer, dosing, trial, groups
Article | 25 July 2005
US groups Vical Inc and Inovio Biomedical have initiated a Phase I study of an investigational method of delivering interleukin-2 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 July 2005
1 August 2005
20 May 2013
© 2013 thepharmaletter.com